Pipeline Review, December 12, 2016
lantForm Corporation is advancing its work on innovative antibody treatments for human immunodeficiency virus (HIV) with a financial contribution of up to $117,400 and technical and business advisory services from the National Research Council of Canada Industry Research Assistance Program (IRAP). It is the third round of funding PlantForm has received from IRAP for the HIV project since 2012, for a total financial contribution of up to $1,484,970.
The new funding will enable PlantForm to continue development, production and testing of antibodies for a potent anti-HIV therapeutic cocktail to treat strains of the disease circulating in sub-Saharan Africa and parts of the developing world. Building upon a $377,000 contribution from IRAP last year, the new agreement will support the current phase of the project until March 31, 2017.
“Sub-Saharan Africa is home to about two-thirds of the 35 million people living with HIV/AIDS – it’s one of the most important public health challenges of our time,” said Dr. Don Stewart, PlantForm’s President and CEO. “It’s essential that we continue working toward our goal of making low-cost, effective and safer drugs available where they are needed most so we can manage and one day eliminate the effects of HIV infection on the world’s most vulnerable populations.”